
Gelişiyor
Business·03.08.2026AI özeti
AstraZeneca CEO Sir Pascal Soriot Faces Scrutiny Over Potential $400bn Bristol Myers Squibb Merger
AstraZeneca CEO Sir Pascal Soriot, 67, is under scrutiny for a potential $400bn merger with Bristol Myers Squibb, which could jeopardize his legacy and expose the company to debt and patent cliff risks.
G
Guardian Business3 dk okuma